The incidence of venous thromboembolism (VTE) is notably high in lung cancer patients, particularly among those treated with immune checkpoint inhibitors (ICIs). Previous studies have focused on the relationship between Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) and VTE risk in immune checkpoint inhibitor therapy, but available evidence is inconsistent. The clinical data of lung cancer patients treated with ICIs were collected and analyzed from West China Hospital between January 2018 and March 2022. ECOG PS score was measured on admission. The primary outcome was the incidence of VTE, encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE). Multivariate logistic regression analysis was conducted to calculate the odds ratio (OR) and 95% confidence interval (95% CI). A total of 1115 lung cancer patients receiving ICIs were eligible for this study, VTE developed in 105 (9.4%) during the 12-month follow-up, of which 95 (8.5%) had DVT,14 (1.3%) had definite PE. Poor ECOG PS (PS ≥ 2) was associated with an increased risk for VTE (OR = 5.405, 95% CI = 3.067–9.525, P < 0.001), DVT (OR = 4.669, 95% CI = 2.588−8.427, P < 0.001) and PE (OR = 8.413, 95% CI = 2.565−27.600, P < 0.001) after multivariable adjustment in the study cohort. VTE occurred in 9.4% of lung cancer patients treated with ICIs, and poor performance status was associated with an increased risk of VTE.

中文翻译：

---

体能状态对免疫检查点抑制剂治疗肺癌患者静脉血栓栓塞的预测价值

肺癌患者中静脉血栓栓塞（VTE）的发生率特别高，尤其是接受免疫检查点抑制剂（ICIs）治疗的患者。先前的研究重点关注免疫检查点抑制剂治疗中东部肿瘤合作组 (ECOG) 体能状态 (PS) 与 VTE 风险之间的关系，但现有证据不一致。收集并分析2018年1月至2022年3月华西医院接受ICIs治疗的肺癌患者的临床资料。入院时测量ECOG PS评分。主要结局是 VTE 的发生率，包括深静脉血栓 (DVT) 和肺栓塞 (PE)。进行多变量逻辑回归分析以计算比值比（OR）和95％置信区间（95％CI）。共有 1115 名接受 ICI 的肺癌患者符合本研究的条件，在 12 个月的随访期间，105 名（9.4%）患者发生 VTE，其中 95 名（8.5%）患有 DVT，14 名（1.3%）患有明确的 PE 。较差的 ECOG PS (PS ≥ 2) 与 VTE 风险增加相关 (OR = 5.405, 95% CI = 3.067–9.525, P < 0.001)、DVT (OR = 4.669, 95% CI = 2.588−8.427, P <研究队列中多变量调整后的 PE（OR = 8.413，95% CI = 2.565−27.600，P < 0.001）。接受 ICI 治疗的肺癌患者中有 9.4% 发生 VTE，体力状态不佳与 VTE 风险增加相关。